Evidence map›Paper›PMID 22448168›Full record

ArticlePPAR research2012

Peroxisome Proliferator-Activated Receptor-γ-Mediated Polarization of Macrophages in Leishmania Infection.

Marion M Chan, Nagasuresh Adapala, Cui Chen

Open access · goldAbstract read
In one paragraph

Article in PPAR research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Frontiers in immunology · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Transcription Factors Interplay Orchestrates the Immune-Metabolic Response ofFrontiers in cellular and infection microbiology · 2021
    Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Marion M ChanDepartment of Microbiology and Immunology, Temple University School of Medicine, Room 534 OMS, 3400 North Broad Street, Philadelphia, PA 19140, USA.
Nagasuresh Adapala
Cui Chen
Temple University · US

Funding

NITRIC OXIDE INHIBITOR AND LEISHMANIA PATHOGENESISR01AI045555 · NIAID · TEMPLE UNIVERSITY · PI CHAN, MARION MAN-YING · 2000 to 2004
$923k
Counterblance in InflammationR21AR051761 · NIAMS · TEMPLE UNIVERSITY · PI CHAN, MARION MAN-YING · 2004 to 2005
$151k
NITRIC OXIDE INHIBITOR AND LEISHMANIA PATHOGENESISR21AI045555 · NIAID · TEMPLE UNIVERSITY · PI CHAN, MARION MAN-YING · 2000 to 2000
$50k
NIAID NIH HHS R01 AI045555NIAID NIH HHS R21 AI045555NIAMS NIH HHS R21 AR051761
6 · The paper itself

Abstract

Infection is the outcome of a contest between a pathogen and its host. In the disease leishmaniasis, the causative protozoan parasites are harbored inside the macrophages. Leishmania species adapt strategies to make the infection chronic, keeping a balance between their own and the host's defense so as to establish an environment that is favorable for survival and propagation. Activation of peroxisome proliferator-activated receptor (PPAR) is one of the tactics used. This ligand-activated nuclear factor curbs inflammation to protect the host from excessive injuries by setting a limit to its destructive force. In this paper, we report the interaction of host PPARs and the pathogen for visceral leishmaniasis, Leishmania donovani, in vivo and in vitro. PPAR expression is induced by parasitic infection. Leishmanial activation of PPARγ promotes survival, whereas blockade of PPARγ facilitates removal of the parasite. Thus, Leishmania parasites harness PPARγ to increase infectivity.

Identifiers

PMID22448168
PMCPMC3289877
OpenAlexW2035987993

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.